Department of Pharmacy, Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, OK, USA.
Department of Pediatrics, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, USA.
Pharmacotherapy. 2021 Apr;41(4):359-369. doi: 10.1002/phar.2515. Epub 2021 Apr 15.
Fentanyl pharmacokinetic and pharmacodynamic data are limited in mechanically ventilated children. This study aimed to assess the fentanyl pharmacokinetics (PK), the sedation outcome, and the development of tolerance in children receiving fentanyl continuous infusion.
This study included children admitted to the pediatric or cardiovascular intensive care unit between January 1 and October 31, 2016, who were >30 days to <18 years of age, receiving ventilatory support via endotracheal tube or tracheostomy, and receiving a fentanyl infusion. Population PK analysis was performed using a nonlinear mixed-effects model. The relationship between initial sedation outcome using State Behavioral Scale (SBS) and fentanyl exposure was assessed, and the observations consistent with tolerance were described.
Seventeen children, with a median age of 0.83 years (range: 0.1-12) and weight of 8.7 kg (range: 3.4-52), were included. The fentanyl PK was adequately described by a weight-based allometry model with the power of 0.75 for clearance (CL=89.8 L/hr/70 kg) and distributional CL, and 1 for volumes of distribution. In infants <6.6 months, age was an additional factor for CL (31.4 L/h/70 kg) to account for age-related maturation. Seven of twelve nonparalyzed patients achieved goal sedation, defined as >80% of SBS scores ≤0 per 24 h, on the first day of fentanyl infusion with a median plasma concentration of 1.29 ng/ml (interquartile range: 0.78-2.05). Eight of the nine tolerant patients developed tolerance within a day of reaching goal sedation.
Different weight-based fentanyl dosing rates may be required for infants and children of different ages to achieve similar plasma concentrations. Using SBS scores may guide the dosing titration of fentanyl that resulted in plasma concentrations within the therapeutic range of 1-3 ng/ml. For those who developed tolerance to fentanyl and/or a sedative, it was noted one day after goal sedation was achieved.
芬太尼的药代动力学和药效动力学数据在机械通气的儿童中有限。本研究旨在评估接受芬太尼持续输注的儿童的芬太尼药代动力学(PK)、镇静结局和耐受性的发展。
本研究纳入 2016 年 1 月 1 日至 10 月 31 日期间入住儿科或心血管重症监护病房的儿童,年龄>30 天至<18 岁,通过气管内管或气管造口术接受通气支持,并接受芬太尼输注。使用非线性混合效应模型进行群体 PK 分析。评估初始镇静结局(使用状态行为量表[SBS])与芬太尼暴露之间的关系,并描述与耐受性一致的观察结果。
纳入 17 名儿童,中位年龄 0.83 岁(范围:0.1-12),体重 8.7kg(范围:3.4-52)。芬太尼 PK 被体重比例模型充分描述,其清除率(CL)的幂为 0.75(CL=89.8 L/hr/70kg)和分布性 CL,以及 1 用于分布容积。在<6.6 个月的婴儿中,年龄是 CL(31.4 L/h/70kg)的附加因素,以解释与年龄相关的成熟度。12 名非麻痹患者中有 7 名在接受芬太尼输注的第一天即达到了目标镇静,定义为 24 小时内 SBS 评分>80%≤0,中位血浆浓度为 1.29ng/ml(四分位距:0.78-2.05)。9 名耐受患者中有 8 名在达到目标镇静后一天内出现耐受。
不同年龄的婴儿和儿童可能需要不同的基于体重的芬太尼给药率,以达到相似的血浆浓度。使用 SBS 评分可能有助于指导芬太尼的剂量滴定,使血浆浓度处于 1-3ng/ml 的治疗范围内。对于那些对芬太尼和/或镇静剂产生耐受的患者,在达到目标镇静后一天就可以注意到。